Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.47 |
| ▸ | TP53 | P04637 | 4/20 | 0.47 |
| ▸ | THRB | P10828 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | AHR | P35869 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL984851 | 0.94 | MAPT (0.48) | MAPTTP53THRBKDM4EMAPK1 | |
| SCHEMBL12923658 | 0.92 | MAPT (0.48) | MAPTTP53THRBKDM4EMAPK1 | |
| SCHEMBL12923661 | 0.91 | MAPT (0.47) | MAPTTP53THRBKDM4EMAPK1 | |
| SCHEMBL983042 | 0.88 | MAPT (0.52) | MAPTTP53THRBKDM4EMAPK1 | |
| SCHEMBL12923655 | 0.87 | MAPT (0.51) | MAPTTP53THRBKDM4EMAPK1 | |
| SCHEMBL12923639 | 0.86 | MAPT (0.46) | MAPTTP53THRBKDM4EMAPK1 | |
| SCHEMBL12923320 | 0.85 | HPGD (0.47) | MAPTTP53MAPK1LMNAALDH1A1 | |
| SCHEMBL12923659 | 0.85 | MAPT (0.46) | MAPTTP53THRBKDM4EMAPK1 | |
| SCHEMBL12923574 | 0.85 | MAPT (0.47) | MAPTTP53THRBKDM4EMAPK1 | |
| SCHEMBL12923666 | 0.84 | MAPT (0.47) | MAPTTP53THRBKDM4EMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009381-A1 | SOLUBILIZED THIAZOLOPYRIDINES | SIRTIS PHARMACEUTICALS, INC. (US) | 2011-01-13 | — | — | US | disclosed |
| US-20110009381-A1 | SOLUBILIZED THIAZOLOPYRIDINES | SIRTIS PHARMACEUTICALS, INC. (US) | 2011-01-13 | — | — | US | disclosed |
| US-20110009381-A1 | SOLUBILIZED THIAZOLOPYRIDINES | SIRTIS PHARMACEUTICALS, INC. (US) | 2011-01-13 | — | — | US | disclosed |
| WO-2009061453-A1 | SOLUBILIZED THIAZOLOPYRIDINES | SIRTRIS PHARMACEUTICALS, INC. (US) | 2009-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009381-A1 | SOLUBILIZED THIAZOLOPYRIDINES | SIRT3, SIRT1, SIRT2 | MAPT 550/4885TP53 515/4885THRB 525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.